Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS

The combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of...

Full description

Bibliographic Details
Main Authors: Patrick Younan, John Kowalski, Hans-Peter Kiem
Format: Article
Language:English
Published: MDPI AG 2013-11-01
Series:Viruses
Subjects:
Online Access:http://www.mdpi.com/1999-4915/5/12/2946
id doaj-1751de6fc77942ac97e2987990d8b7f8
record_format Article
spelling doaj-1751de6fc77942ac97e2987990d8b7f82020-11-24T21:54:35ZengMDPI AGViruses1999-49152013-11-015122946296210.3390/v5122946v5122946Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDSPatrick Younan0John Kowalski1Hans-Peter Kiem2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAThe combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of HSCs is an ideal strategy for the development of infection-resistant immune cell populations. Although promising results have been obtained in multiple animal models, additional evidence is needed to convincingly demonstrate the feasibility of this approach as a treatment of HIV-1 infected patients. Here, we review the potential of HSC transplantation and the recently identified limitations of this approach. Using the Berlin Patient as a model for a functional cure, we contrast the confines of autologous versus allogeneic transplantation. Finally, we suggest that although autologous, gene-modified HSC-transplantation may significantly reduce plasma viremia, reaching the lower detection limits currently obtainable through daily HAART will remain a challenging endeavor that will require innovative combinatorial therapies.http://www.mdpi.com/1999-4915/5/12/2946HIV/AIDSGene TherapyStem Cell Transplantation
collection DOAJ
language English
format Article
sources DOAJ
author Patrick Younan
John Kowalski
Hans-Peter Kiem
spellingShingle Patrick Younan
John Kowalski
Hans-Peter Kiem
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
Viruses
HIV/AIDS
Gene Therapy
Stem Cell Transplantation
author_facet Patrick Younan
John Kowalski
Hans-Peter Kiem
author_sort Patrick Younan
title Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
title_short Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
title_full Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
title_fullStr Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
title_full_unstemmed Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
title_sort genetic modification of hematopoietic stem cells as a therapy for hiv/aids
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2013-11-01
description The combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of HSCs is an ideal strategy for the development of infection-resistant immune cell populations. Although promising results have been obtained in multiple animal models, additional evidence is needed to convincingly demonstrate the feasibility of this approach as a treatment of HIV-1 infected patients. Here, we review the potential of HSC transplantation and the recently identified limitations of this approach. Using the Berlin Patient as a model for a functional cure, we contrast the confines of autologous versus allogeneic transplantation. Finally, we suggest that although autologous, gene-modified HSC-transplantation may significantly reduce plasma viremia, reaching the lower detection limits currently obtainable through daily HAART will remain a challenging endeavor that will require innovative combinatorial therapies.
topic HIV/AIDS
Gene Therapy
Stem Cell Transplantation
url http://www.mdpi.com/1999-4915/5/12/2946
work_keys_str_mv AT patrickyounan geneticmodificationofhematopoieticstemcellsasatherapyforhivaids
AT johnkowalski geneticmodificationofhematopoieticstemcellsasatherapyforhivaids
AT hanspeterkiem geneticmodificationofhematopoieticstemcellsasatherapyforhivaids
_version_ 1725867129021923328